Limits...
PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer

View Article: PubMed Central - PubMed

ABSTRACT

Lung adenosquamous cell carcinomas (ASCs) is a rare variant of NSCLC with a poorer prognosis and fewer treatment option than the more common variants. PD-L1 expression is reported to be the predictor of clinical response in trials of NSCLC. In our study, PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP263), and PD-L1 mRNA expression was evaluated via in situ hybridization. This study included 51 ASCs, 133 lung adenocarcinomas, and 83 lung squamous cell carcinomas (SCC). Similar results were obtained for PD-L1 expression measured at the mRNA and protein level (k coefficient, 0.851, P = 1.000). PD-L1 expression was significantly higher in the squamous versus glandular component of the 36 ASCs in which the components were analyzed separately. The PD-L1 expression rate was similar in the squamous cell component of ASCs and lung SCC (38.89% vs. 28.92%, P = 0.293), so does the adenocarcinoma component of ASCs and lung adenocarcinomas (11.11% vs 13.53%, P = 1.000). PD-L1 expression correlated significantly with lymphovascular invasion (P = 0.016), but not with EGFR, KRAS, and ALK mutations in lung ASCs. Anit-PD-L1 is a promising treatment option in lung ASC cases in which PD-L1 upregulated and EGFR mutations are present.

No MeSH data available.


Related in: MedlinePlus

Kaplan–Meier survival curves.(a) The was no significant difference regarding overall survival between PD-L1 positive and negative group. (b) The was no significant difference regarding recurrence free survival between PD-L1 positive and negative group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC5384250&req=5

f2: Kaplan–Meier survival curves.(a) The was no significant difference regarding overall survival between PD-L1 positive and negative group. (b) The was no significant difference regarding recurrence free survival between PD-L1 positive and negative group.

Mentions: After surgery, 29 of 49 patients received adjuvant therapy, including chemotherapy (28 patients), radiation therapy (10 patients), or both (9 patients). None of them received anti PD-1 or PD-L1 targeted therapy. Survival data were available for 49 of the 51 lung ASC patients (three patients were further lost to follow-up after disease recurrence). Tumors recurred or metastasized in 20 (40.82%) of the 49 patients at an average time of 14.03 months (range: 1–54 months) after surgery. Twelve (25.53%) of 47 patients died within an average time of 14.89 months (range: 0–33 months) after surgery. At the end of the follow-up period, 22 patients were alive without disease. There were no association between either OS or RFS and PD-L1 protein expression (P = 0.885 and 0.474, respectively) (Fig. 2).


PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer
Kaplan–Meier survival curves.(a) The was no significant difference regarding overall survival between PD-L1 positive and negative group. (b) The was no significant difference regarding recurrence free survival between PD-L1 positive and negative group.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC5384250&req=5

f2: Kaplan–Meier survival curves.(a) The was no significant difference regarding overall survival between PD-L1 positive and negative group. (b) The was no significant difference regarding recurrence free survival between PD-L1 positive and negative group.
Mentions: After surgery, 29 of 49 patients received adjuvant therapy, including chemotherapy (28 patients), radiation therapy (10 patients), or both (9 patients). None of them received anti PD-1 or PD-L1 targeted therapy. Survival data were available for 49 of the 51 lung ASC patients (three patients were further lost to follow-up after disease recurrence). Tumors recurred or metastasized in 20 (40.82%) of the 49 patients at an average time of 14.03 months (range: 1–54 months) after surgery. Twelve (25.53%) of 47 patients died within an average time of 14.89 months (range: 0–33 months) after surgery. At the end of the follow-up period, 22 patients were alive without disease. There were no association between either OS or RFS and PD-L1 protein expression (P = 0.885 and 0.474, respectively) (Fig. 2).

View Article: PubMed Central - PubMed

ABSTRACT

Lung adenosquamous cell carcinomas (ASCs) is a rare variant of NSCLC with a poorer prognosis and fewer treatment option than the more common variants. PD-L1 expression is reported to be the predictor of clinical response in trials of NSCLC. In our study, PD-L1 expression was evaluated via immunohistochemistry using a specific monoclonal antibody (SP263), and PD-L1 mRNA expression was evaluated via in situ hybridization. This study included 51 ASCs, 133 lung adenocarcinomas, and 83 lung squamous cell carcinomas (SCC). Similar results were obtained for PD-L1 expression measured at the mRNA and protein level (k coefficient, 0.851, P = 1.000). PD-L1 expression was significantly higher in the squamous versus glandular component of the 36 ASCs in which the components were analyzed separately. The PD-L1 expression rate was similar in the squamous cell component of ASCs and lung SCC (38.89% vs. 28.92%, P = 0.293), so does the adenocarcinoma component of ASCs and lung adenocarcinomas (11.11% vs 13.53%, P = 1.000). PD-L1 expression correlated significantly with lymphovascular invasion (P = 0.016), but not with EGFR, KRAS, and ALK mutations in lung ASCs. Anit-PD-L1 is a promising treatment option in lung ASC cases in which PD-L1 upregulated and EGFR mutations are present.

No MeSH data available.


Related in: MedlinePlus